Phenotec AG

The core activity of PhenoTec AG is the development and optimization of drug candidates, particularly for the treatment of chronic inflammatory diseases such as allergic asthma, chronic obstructive pulmonary disease (COPD), fibrosis, acute respiratory distress syndrome (ARDS), and viral infections such as influenza or COVID-19. To this end, the company offers services such as preclinical studies, in vitro and in vivo investigations, mechanism studies, and consulting for the development of new therapeutics. A specific product being developed by PhenoTec is PB, a novel anti-inflammatory butyrate derivative intended for the treatment of chronic inflammatory lung and skin diseases.